Adicet Bio to Present at Upcoming Investor Conferences
June 21 2022 - 4:10PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first-in-class allogeneic gamma
delta chimeric antigen receptor (CAR) T cell therapies for cancer,
today announced that company management will participate in two
upcoming investor conferences in June.
Details of the events are as follows:
Truist Securities Cell Therapy Symposium, Symposia-cel, June 28,
2022
- Chen Schor, President & CEO, will participate in a panel
discussion titled, “The Next Cells & Mechanisms to Watch in
Oncology” on Tuesday, June 28, 2022, at 11:30 A.M. ET.
Stifel 2022 Virtual Cell Therapy Summit, June 29-30, 2022
- Chen Schor, President & CEO, will participate in a panel
discussion titled, “Outlining the Potential of New Cell Types and
Novel Approaches” on Wednesday, June 29, 2022, at 1:00 P.M.
ET.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with CAR and T cell receptor-like
targeting moieties to enhance selective tumor targeting, facilitate
innate and adaptive anti-tumor immune response, and improve
persistence for durable activity in patients. For more information,
please visit our website at http://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621005986/en/
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024